|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0205179,
umls-concept:C0205208,
umls-concept:C0444889,
umls-concept:C0681850,
umls-concept:C0877874,
umls-concept:C0920321,
umls-concept:C1521801,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C2349001,
umls-concept:C2697811
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-2-4
|
|
pubmed:abstractText |
Troxacitabine is a novel L-nucleoside analogue. Preclinical studies showed improved activity with infusions of at least 3 days compared with bolus regimens, especially at concentrations >20 ng/ml. This phase I study tested the feasibility of achieving a troxacitabine steady-state concentration of 20 ng/ml for at least 72 h in patients with solid tumors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
374-9
|
|
pubmed:meshHeading |
pubmed-meshheading:18245131-Adult,
pubmed-meshheading:18245131-Aged,
pubmed-meshheading:18245131-Cytosine,
pubmed-meshheading:18245131-Dioxolanes,
pubmed-meshheading:18245131-Dose-Response Relationship, Drug,
pubmed-meshheading:18245131-Drug Administration Schedule,
pubmed-meshheading:18245131-Drug Toxicity,
pubmed-meshheading:18245131-Feasibility Studies,
pubmed-meshheading:18245131-Female,
pubmed-meshheading:18245131-Follow-Up Studies,
pubmed-meshheading:18245131-Humans,
pubmed-meshheading:18245131-Immunohistochemistry,
pubmed-meshheading:18245131-Infusions, Intravenous,
pubmed-meshheading:18245131-Male,
pubmed-meshheading:18245131-Maximum Tolerated Dose,
pubmed-meshheading:18245131-Middle Aged,
pubmed-meshheading:18245131-Neoplasm Invasiveness,
pubmed-meshheading:18245131-Neoplasm Staging,
pubmed-meshheading:18245131-Neoplasms,
pubmed-meshheading:18245131-Predictive Value of Tests,
pubmed-meshheading:18245131-Probability,
pubmed-meshheading:18245131-Risk Assessment,
pubmed-meshheading:18245131-Survival Analysis,
pubmed-meshheading:18245131-Time Factors,
pubmed-meshheading:18245131-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
|
|
pubmed:affiliation |
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
